| 1. Deposition is between 8% and 16% of metered dose |
| |
| The lung deposition of terbutaline and budesonide has been investigated in several studies employing a variety of methods. Typically, values of 8–17% were obtained.
|
| |
| 2. Newman S, et al. Pharm Res 1995; 12: 231–6 |
| |
| The deposition of terbutaline was determined by both gamma scintigraphy and the charcoal block pharmacokinetic method. Similar deposition values were recorded for both methods. At low inspiratory flow rate (30 L/min) values were 10.7% and 11.2%, respectively; at a higher flow rate (180 L/min) values were 10.4% and 7.2%, respectively.
Lung deposition following actuation of a pMDI is greater at low flow rates than high flow rates
Adapted from Newman et al., 1995.
|
| |
| 3. Pauwels R, et al. Eur Respir J 1997; 10: 2127–38 |
| |
| This review summarizes the deposition and effects of a variety of drugs delivered to the lungs via pMDIs or dry powder inhalers. Lung deposition values for terbutaline and budesonide ranged between 8.2% and 16.7%.
|
| |
| 4. Correct use of a spacer with a pMDI results in substantially greater lung deposition |
| |
|
Clinical improvements in lung function for a given dose of inhaler are markedly increased when a spacer device is used correctly in conjunction with a pMDI. Please access the NebuChamber and Nebuhaler sections for more information on spacers.
|
| |
| 5. Newman S, et al. Pharm Res 1995; 12: 231–6 |
| |
|
The deposition of terbutaline was determined by both gamma scintigraphy and the charcoal block pharmacokinetic method. Similar deposition values were recorded for both methods. When the Nebuhaler spacer was used (inspiratory flow rate of 15 L/min), values were 31.6% and 33.8%, respectively, approximately three times those obtained when a spacer was not used.
Correct use of a spacer markedly increases lung deposition from a pMDI
Adapted from Newman et al., 1995.
|
| |
back to top 
|
